Pfizer Discontinues Development of Two Phase 3 Compounds
- Details
- Category: Pfizer
Pfizer Inc has announced that, following a review of the development and commercial portfolios in the Primary Care Business Unit, it is terminating Phase 3 development programs for the investigational compounds esreboxetine for fibromyalgia and PD 332,334 for generalized anxiety disorder (GAD).
Nycomed reports a satisfactory 2008
- Details
- Category: Nycomed
For Nycomed the twelve months of 2008 have been satisfactory and most of the markets performed well and met expectations. Key products developed strongly, with the exception of Pantoprazole sales in the United States and Canada, which is due to âat-riskâ launch and generic competition, respectively. The company's integration restructuring showed its full cost-savings effect in 2008.
Schering-Plough announces collaboration with World Health Organization
- Details
- Category: Business
Schering-Plough Corporation (NYSE: SGP) has announced a license agreement between Nobilon, Schering-Plough's human vaccine business unit, and the World Health Organization (WHO) to provide access to pandemic influenza vaccine manufacturing technology to developing countries.
Encouraging results support further development of Almirall's long-acting beta-agonist (LABA)
- Details
- Category: Clinical Trials
Further to the results of prior studies published last year, Almirall, the international pharmaceutical company based in Spain, announced new Phase II multi-dose study results demonstrating that its novel once-daily, inhaled, long-acting beta-agonist (LABA) -LAS100977-, for the treatment of bronchoconstriction in asthmatic patients, shows fast-acting and 24-hour efficacy, as well as a good safety and tolerability profile in patients during multiple dose administrations.
Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics
- Details
- Category: Abbott
Abbott (NYSE: ABT) has received merger control clearance from the European Commission for its acquisition of Advanced Medical Optics (AMO) through a cash tender offer for the outstanding shares of common stock of AMO. The European Commission approved the transaction without conditions.
The safety of patients is of utmost importance to Merck
- Details
- Category: Merck Group
Merck KGaA announced that the European Medicines Agency (EMEA) has recommended to the European Commission the suspension of the marketing authorization for Raptiva® (efalizumab). Raptiva is currently approved for the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to certain other systemic therapies.
GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline has announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria® (albiglutide) in men and women with type 2 diabetes. The Phase III programme will include more than 4,000 patients.
More Pharma News ...
- FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
- Bristol-Myers Squibb Foundation to Bridge Gaps in Hepatitis C Awareness, Prevention and Care
- Immune-boosting effect of Pegasys provides patients with the chance for a clinical cure
- New England Journal of Medicine publishes results from the landmark ATHENA trial
- Sandoz receives European Commission approval for biosimilar filgrastim
- Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound
- Bayer Schering Pharma to invest 100 million Euro in China to build a global R&D center